AbCellera Biologics Inc. Common Shares ABCL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T16:37:36.554Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:51:34.746442Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-07T16:37:36.137175+00:00
AbCellera Biologics Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.53 | 110.7% | 24.7% | 10.01 | 125.4% | 18.6% |
| 25Δ | 14.04 | 113.3% | 21.3% | 10.39 | 125.7% | 16.5% |
| 30Δ | 13.63 | 113.9% | 18.7% | 10.77 | 126.0% | 14.4% |
| 35Δ | 13.23 | 114.3% | 16.1% | 11.15 | 126.3% | 12.5% |
| 40Δ | 12.86 | 117.0% | 14.1% | 11.51 | 126.6% | 11.0% |
| 45Δ | 12.54 | 122.7% | 12.8% | 11.86 | 127.0% | 9.5% |
| 50Δ | 12.22 | 128.5% | 11.5% | 12.29 | 132.8% | 8.5% |
| 55Δ | 11.87 | 133.1% | 10.2% | 12.77 | 142.2% | 7.7% |
| 60Δ | 11.49 | 135.4% | 8.7% | 13.24 | 146.0% | 6.7% |
| 65Δ | 11.11 | 137.6% | 7.3% | 13.71 | 144.6% | 5.5% |
| 70Δ | 10.83 | 129.3% | 5.9% | 14.27 | 145.3% | 4.4% |
| 75Δ | 10.60 | 116.7% | 4.6% | 14.98 | 149.3% | 3.5% |
| 80Δ | 10.36 | 104.0% | 3.2% | 16.47 | 168.6% | 2.9% |
20Δ
- Pseudo strike
- 14.53
- IV
- 110.7%
- B/E move
- 24.7%
- Pseudo strike
- 10.01
- IV
- 125.4%
- B/E move
- 18.6%
25Δ
- Pseudo strike
- 14.04
- IV
- 113.3%
- B/E move
- 21.3%
- Pseudo strike
- 10.39
- IV
- 125.7%
- B/E move
- 16.5%
30Δ
- Pseudo strike
- 13.63
- IV
- 113.9%
- B/E move
- 18.7%
- Pseudo strike
- 10.77
- IV
- 126.0%
- B/E move
- 14.4%
35Δ
- Pseudo strike
- 13.23
- IV
- 114.3%
- B/E move
- 16.1%
- Pseudo strike
- 11.15
- IV
- 126.3%
- B/E move
- 12.5%
40Δ
- Pseudo strike
- 12.86
- IV
- 117.0%
- B/E move
- 14.1%
- Pseudo strike
- 11.51
- IV
- 126.6%
- B/E move
- 11.0%
45Δ
- Pseudo strike
- 12.54
- IV
- 122.7%
- B/E move
- 12.8%
- Pseudo strike
- 11.86
- IV
- 127.0%
- B/E move
- 9.5%
50Δ
- Pseudo strike
- 12.22
- IV
- 128.5%
- B/E move
- 11.5%
- Pseudo strike
- 12.29
- IV
- 132.8%
- B/E move
- 8.5%
55Δ
- Pseudo strike
- 11.87
- IV
- 133.1%
- B/E move
- 10.2%
- Pseudo strike
- 12.77
- IV
- 142.2%
- B/E move
- 7.7%
60Δ
- Pseudo strike
- 11.49
- IV
- 135.4%
- B/E move
- 8.7%
- Pseudo strike
- 13.24
- IV
- 146.0%
- B/E move
- 6.7%
65Δ
- Pseudo strike
- 11.11
- IV
- 137.6%
- B/E move
- 7.3%
- Pseudo strike
- 13.71
- IV
- 144.6%
- B/E move
- 5.5%
70Δ
- Pseudo strike
- 10.83
- IV
- 129.3%
- B/E move
- 5.9%
- Pseudo strike
- 14.27
- IV
- 145.3%
- B/E move
- 4.4%
75Δ
- Pseudo strike
- 10.60
- IV
- 116.7%
- B/E move
- 4.6%
- Pseudo strike
- 14.98
- IV
- 149.3%
- B/E move
- 3.5%
80Δ
- Pseudo strike
- 10.36
- IV
- 104.0%
- B/E move
- 3.2%
- Pseudo strike
- 16.47
- IV
- 168.6%
- B/E move
- 2.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 93.66% | |
| 86.27% | |
| 91.47% | |
| 89.80% | |
| 87.72% | |
| 100.57% | |
| 92.95% | |
| 99.80% | |
| 116.58% | |
| 88.14% | |
| 85.96% | |
| 91.64% | |
| 88.52% | |
| 88.05% | |
| 84.68% | |
| 90.59% | |
| 83.85% | |
| 82.79% | |
| 83.75% | |
| 82.50% | |
| 87.19% | |
| 82.60% | |
| 82.67% | |
| 87.84% | |
| 89.18% | |
| 85.87% | |
| 89.38% | |
| 87.73% | |
| 88.59% | |
| 85.33% | |
| 84.64% | |
| 88.95% | |
| 92.02% | |
| 93.16% | |
| 92.27% | |
| 87.60% | |
| 82.89% | |
| 81.29% | |
| 78.46% | |
| 82.69% | |
| 80.79% | |
| 78.90% | |
| 84.55% | |
| 86.71% | |
| 83.40% | |
| 83.93% | |
| 83.56% | |
| 82.09% | |
| 77.09% | |
| 82.59% | |
| 81.85% | |
| 79.16% | |
| 84.47% | |
| 83.10% | |
| 86.45% | |
| 88.70% |
Biotechnology
ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in…
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →ABSI
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid…
More →ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus…
More →ABVX
Description unavailable
More →ACAD
Description unavailable
More →